美國居民不適用 XM 服務。
B
B

Biomarin

交易方向

交易者脈動

技術摘要

小時

財經新聞

BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies

REFILE-UPDATE 2-BioMarin Pharma gets DOJ subpoena on sponsored testing programs for two therapies Corrects to fix typographical error in story identifier Feb 26 (Reuters) - BioMarin Pharmaceutical BMRN.O has received a subpoena from the U.S. Department of Justice seeking information about the company's sponsored testing programs related to two treatments, the therapy maker said in a filing on Monday.
B

BioMarin Pharma gets DOJ subpoena on certain drug testing programs

REFILE-BioMarin Pharma gets DOJ subpoena on certain drug testing programs Corrects to fix typographical error in story identifier Feb 26 (Reuters) - BioMarin Pharmaceutical BMRN.O has received a subpoena from the U.S. Department of Justice seeking information about the company's sponsored testing programs related to two treatments, it said in a filing on Monday.
B

U.S. Elf Beauty, Moderna, Zscaler

U.S. RESEARCH ROUNDUP-Elf Beauty, Moderna, Zscaler Feb 26 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Elf Beauty, Moderna, and Zscaler, on Monday. HIGHLIGHTS * Elf Beauty Inc ELF.N : Piper Sandler raises target price to $225 from $212 * Elevance Health Inc ELV.N : JP Morgan raises target price to $560 from $552 * Moderna MRNA.O : HSBC cuts to reduce from hold * Molina Healthcare Inc MOH.N : JP Morgan raises target
A
B
B
B
G
L
D
H
C
D

U.S. STOCKS Hyatt Hotels, Morningstar Inc, SunPower Corp

BUZZ-U.S. STOCKS ON THE MOVE-Hyatt Hotels, Morningstar Inc, SunPower Corp Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes lost momentum on Friday following a dizzying rally fueled by euphoria around artificial intelligence that briefly vaulted Nvidia to over $2 trillion in market valuation for the first time.
B
D
N
U
U
L
L

BioMarin climbs after Q4 revenue beat

BUZZ-BioMarin climbs after Q4 revenue beat ** Shares of therapy developer BioMarin Pharmaceutical BMRN.O rise ~1% to $90.87 ** Company's quarterly revenue of $646.2 mln beats analysts' average expectation of $636.9 mln - LSEG data ** Says revenue for its dwarfism therapy Voxzogo grew 18% over the prior quarter, positively impacted by an increase in prescriptions for children under the age of 5 in the U.S.
B

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明